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Analyzing Compliance with the NICU Neonatal Abstinence
Syndrome Pathway
Elizabeth Guju MS4; Wendy Kowalski M.D.
Lehigh Valley Health Network, Allentown, Pennsylvania

Background
• Neonatal abstinence syndrome (NAS) is a withdrawal
syndrome of newborns that develops after birth with
the abrupt discontinuation of in utero exposure to
drugs of abuse. It typically manifests in the first few
days of life and clinical symptoms include neurologic
excitability, autonomic instability, impaired weight gain,
irritability, and gastrointestinal dysfunction.
• It has been shown that an algorithmic management of
NAS is useful for the standardization of management
in order to ensure all infants at risk are identified and
receive proper treatment and outpatient follow-up.
• Specifically, clinical pathways are common tools used
to standardize the care processes in order to
maximize patient outcomes and improve
organizational efficiency.
• Lehigh Valley Health Network (LVHN) aims to provide
the best quality of maternal and neonatal care through
implementation of the multidisciplinary
Comprehensive Pathway for Perinatal Substance
Abuse. (Figure 1) This pathway was developed to
ensure all mothers with substance abuse and their
infants at risk for NAS, or with NAS, are identified,
treated, and followed after discharge. Pathway
compliance has not previously been assessed.

Results
•
•
•
•

A total of 161 charts were pulled due to having either UDS10 or
MecDS code ordered.
2 charts were excluded (refer to Table 2 for full description of
analyzed groups).
Refer to Table 3 for percentage compliance at each compliance
point 1 through 6.
Qualitative data regarding documented provider reasoning for
non-compliance with compliance points 5 and 6 is presented in
Table 4.

Problem Statement

Discussion
General Discussion:
•
The only compliance point that met 100% goal was referral to OCYS.
•
Compliance point 1 had 88.05% compliance. Reasons for non-compliance may be late
order entry or late attempt at collecting the urine/meconium samples. Orders must be placed in
a timely manner after birth for results to be reliable. Providers also occasionally cancel the
Meconium drug screen when the urine is resulted as negative, which is inappropriate and
requires re-education.
–
To improve compliance: An order set that includes Finnegan scoring and both drug screens was
developed and is currently in the process of being incorporated into the EPIC electronic medical
record.
•
Compliance point 2 had 84.90% compliance. Reasoning for non-compliance may include
clinical time limitations for nursing staff with Finnegan scoring as well as miss-education of
providers of when Finnegan scoring needs to be conducted. Upon initial data assessment it
appeared that compliance with scoring was even worse; however, the majority of babies that
did not get Finnegan scoring were preterm infants who were NPO and/or on narcotics for
surgery. Finnegan scoring has not been validated, nor is it appropriate, for either of these
populations.
–
To improve compliance: Re-education about when to start Finnegan scoring and on which babies.
•
Compliance point 3a had 100% compliance and point 3b had 71.43%. One contributing
factor for apparent non-compliance with the CAC follow-up is that babies of mothers, who are
compliant with prescribed medications, such as suboxone or methadone, who are not showing
any signs of NAS, or whose mothers are in a program for chronic pain or narcotic abuse, do
not actually need OCYS referral or CAC follow-up.
–
To improve compliance: Guidelines regarding this are not currently well specified in the pathway;
modification will be made with clear guidelines on who should be seen in CAC after discharge,
regardless if an OCYS referral was indicated.
•
Compliance point 4 met closes to 100% goal at 94.45% compliance. Reasons for noncompliance include the subjective nature of the scoring. There is NICU provider discretion
allowed for choosing to keep the infant with Mom in MBU if an elevated score is felt to be due
to environmental factors and there is no required use of non-pharmacological measures for
NAS.
–
To improve compliance: Re-education of mom and nursing would allow infants to be calmed with
non-pharmacologic measures and reduce need to come to NICU or need medications.
•
Compliance point 5 and 6 had 73.33% and 60.00% compliance. Based off of qualitative
data collected if was determined that often babies with borderline scores, aka scores close to
8, will not get weaned daily for provider fear of making them withdraw more. This practice only
increases the length of stay (LOS) for these babies.
–
To improve compliance: Re-education of providers with encouragement to continue to wean
morphine as long as scores are <8.
Project limitations:
•
Compliance was measured only through assessment of documentation in EPIC.
SELECT Principles:
•
A quality improvement project focused on the SELECT domain of health systems.
•
NAS caries an enormous burden in terms of hospital days and costs.
•
Using data obtained from this project, LVHN is able to improve standardization of care, for both
inpatient and outpatient follow-up, to mother of infants and infants with NAS.

• This is a quality improvement project designed to assess
compliance and non-compliance (in percentage %) with
the LVHN multidisciplinary Comprehensive Pathway for
Perinatal Substance Abuse.

Conclusions

Methods

• Overall, this project assessed compliance with the
Comprehensive Pathway for Perinatal Substance
Abuse and determined that only one compliance point
met the 100% compliance goal.
• Data gathered allowed departments (Obstetrics, NICU,
MBU) to identify areas where pathway compliance is
low so that changes could be implemented.
• Possible reasons for non-compliance were discussed
within the involved departments.
• Current and future changes include:

• Internally designed quality improvement project within
the LVHN Labor and Delivery, NICU, and Mother Baby
Units.
• Retrospective chart review of neonates placed on the
Comprehensive Pathway for Perinatal Substance
Abuse (from July 1, 2017- July 1, 2018).
• Charts identified using a urine (UDS-10) or meconium
(MecDS) drug screen code.
• Exclusion criteria: the baby died or the baby was
transferred to an outside center for care.
• Pathway compliance was measured using 6 predetermined compliance points (see Table 1).
• Number of charts included for each compliance point
was determined on chart-by-chart basis, as following
the Comprehensive Pathway for Perinatal Substance
Abuse.
• Chart review of consisted of looking through EPIC
specifically in the clinical notes, lab orders, and
nursing flow-sheets tab.
• Percent compliance and non-compliance with the
pathway was determined for each compliance point.
• Qualitative data for 5-6 recorded.
• Goal for pathway compliance was set at 100% for
each compliance point 1 through 6.

–
–
–
–

development of order sets that include both
urine/meconium drug screens and Finnegan scoring
non-pharmacologic management of NAS
modification of the pathway to better define
outpatient follow-up needs
re-education of nursing and providers regarding
proper Finnegan scoring and morphine weaning
protocols.
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Figure 1: Comprehensive Pathway for Perinatal Substance Abuse
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